Bank of New York Mellon’s Crescent Biopharma CBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $824K | Buy |
+45,778
| New | +$894K | ﹤0.01% | 3477 |
|
|
2024
Q1 | – | Sell |
-247
| Closed | -$58.4K | – | 4222 |
|
|
2023
Q4 | $58.4K | Sell |
247
-2
| -0.8% | -$311 | ﹤0.01% | 4145 |
|
|
2023
Q3 | $37.3K | Sell |
249
-2
| -0.8% | -$316 | ﹤0.01% | 4189 |
|
|
2023
Q2 | $43.7K | Sell |
251
-1
| -0.4% | -$168 | ﹤0.01% | 4197 |
|
|
2023
Q1 | $31.7K | Sell |
252
-10
| -4% | -$2.25K | ﹤0.01% | 4258 |
|
|
2022
Q4 | $79.3K | Hold |
262
| – | – | ﹤0.01% | 4164 |
|
|
2022
Q3 | $14K | Hold |
262
| – | – | ﹤0.01% | 4482 |
|
|
2022
Q2 | $16K | Sell |
262
-1
| -0.4% | -$74 | ﹤0.01% | 4513 |
|
|
2022
Q1 | $30K | Hold |
263
| – | – | ﹤0.01% | 4588 |
|
|
2021
Q4 | $38K | Hold |
263
| – | – | ﹤0.01% | 4537 |
|
|
2021
Q3 | $58K | Sell |
263
-4
| -1% | -$847 | ﹤0.01% | 4410 |
|
|
2021
Q2 | $62K | Sell |
267
-1,096
| -80% | -$279K | ﹤0.01% | 4295 |
|
|
2021
Q1 | $410K | Buy |
1,363
+41
| +3% | +$14.7K | ﹤0.01% | 3794 |
|
|
2020
Q4 | $496K | Buy |
1,322
+30
| +2% | +$10.5K | ﹤0.01% | 3623 |
|
|
2020
Q3 | $397K | Buy |
1,292
+30
| +2% | +$11.5K | ﹤0.01% | 3600 |
|
|
2020
Q2 | $474K | Buy |
1,262
+43
| +4% | +$12.2K | ﹤0.01% | 3510 |
|
|
2020
Q1 | $278K | Buy |
1,219
+89
| +8% | +$34K | ﹤0.01% | 3632 |
|
|
2019
Q4 | $598K | Sell |
1,130
-243
| -18% | -$132K | ﹤0.01% | 3497 |
|
|
2019
Q3 | $592K | Sell |
1,373
-87
| -6% | -$56K | ﹤0.01% | 3442 |
|
|
2019
Q2 | $1.74M | Sell |
1,460
-4
| -0.3% | -$4.78K | ﹤0.01% | 2871 |
|
|
2019
Q1 | $1.82M | Buy |
1,464
+22
| +2% | +$25.2K | ﹤0.01% | 2828 |
|
|
2018
Q4 | $1.36M | Buy |
1,442
+28
| +2% | +$33.7K | ﹤0.01% | 2926 |
|
|
2018
Q3 | $2.04M | Buy |
1,414
+30
| +2% | +$45.4K | ﹤0.01% | 2823 |
|
|
2018
Q2 | $2.23M | Buy |
1,384
+1,043
| +306% | +$1.79M | ﹤0.01% | 2791 |
|
|
2018
Q1 | $554K | Sell |
341
-536
| -61% | -$1.11M | ﹤0.01% | 3544 |
|
|
2017
Q4 | $1.47M | Sell |
877
-61
| -7% | -$80.7K | ﹤0.01% | 3020 |
|
|
2017
Q3 | $1.31M | Buy |
938
+9
| +1% | +$10.6K | ﹤0.01% | 3077 |
|
|
2017
Q2 | $1.04M | Buy |
929
+571
| +159% | +$472K | ﹤0.01% | 3230 |
|
|
2017
Q1 | $195K | Hold |
358
| – | – | ﹤0.01% | 3886 |
|
|
2016
Q4 | $219K | Buy |
358
+10
| +3% | +$6.24K | ﹤0.01% | 3873 |
|
|
2016
Q3 | $249K | Buy |
348
+51
| +17% | +$39K | ﹤0.01% | 3831 |
|
|
2016
Q2 | $216K | Buy |
+297
| New | +$205K | ﹤0.01% | 3873 |
|
|
2014
Q2 | – | Sell |
-205
| Closed | -$335K | – | 4193 |
|
|
2014
Q1 | $335K | Buy |
+205
| New | +$248K | ﹤0.01% | 3704 |
|
Other funds holding CBIO
RCP
YIH
N
QC
Bank of New York Mellon's CBIO Position: Q2 2026 in Review
Bank of New York Mellon opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 45,778 shares worth $824K. The stake represents ﹤0.01% of the portfolio and ranks #3477 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in CBIO as recently as Q4 2023.
Bank of New York Mellon first reported a position in CBIO in Q1 2014 and has held it in 33 quarters since. The position peaked at $2.23M in Q2 2018. 29 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.
- Bank of New York Mellon held 45,778 shares of Crescent Biopharma worth $824K as of Q2 2026.
- Crescent Biopharma was a new Bank of New York Mellon position in Q2 2026.
- Crescent Biopharma made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3477 holding.
- Bank of New York Mellon first reported a position in Crescent Biopharma in Q1 2014 and has held it in 33 quarters since.
- Bank of New York Mellon's Crescent Biopharma position peaked at $2.23M in Q2 2018.
- 29 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.